These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17659581)

  • 21. A study to investigate the impact of the initiation of highly active antiretroviral therapy on the hepatitis C virus viral load in HIV/HCV-coinfected patients.
    Mijch A; Sasadeusz J; Hellard M; Dunne M; McCaw R; Bowden S; Gowans EJ
    Antivir Ther; 2005; 10(2):277-84. PubMed ID: 15865222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV and hepatitis C coinfection.
    Matthews GV; Dore GJ
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HCV genotype analysis in HCV-HIV-co-infected Puerto Ricans who are injecting drug users: undetermined and mixed infections.
    Ríos-Olivares E; Yamamura Y; Gómez MA; Guzmán L; Rodríguez N; Fernández D; Hunter Mellado R
    Cell Mol Biol (Noisy-le-grand); 2001 Sep; 47(6):1017-24. PubMed ID: 11785651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin.
    Bukowska-Ośko I; Pawełczyk A; Perlejewski K; Kubisa N; Caraballo Cortés K; Rosińska M; Płoski R; Fic M; Kaźmierczak J; Popiel M; Ząbek P; Horban A; Radkowski M; Laskus T
    PLoS One; 2015; 10(5):e0125604. PubMed ID: 25932941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends for genetic variation of Hepatitis C Virus quasispecies in Human Immunodeficiency virus-1 coinfected patients.
    López-Labrador FX; Dove L; Hui CK; Phung Y; Kim M; Berenguer M; Wright TL
    Virus Res; 2007 Dec; 130(1-2):285-91. PubMed ID: 17601623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Within-host dynamics of the hepatitis C virus quasispecies population in HIV-1/HCV coinfected patients.
    Bernini F; Ebranati E; De Maddalena C; Shkjezi R; Milazzo L; Lo Presti A; Ciccozzi M; Galli M; Zehender G
    PLoS One; 2011 Jan; 6(1):e16551. PubMed ID: 21304985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.
    Shire NJ; Horn PS; Rouster SD; Stanford S; Eyster ME; Sherman KE;
    Hepatology; 2006 Nov; 44(5):1146-57. PubMed ID: 17058240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fosamprenavir treatment in a highly active antiretroviral therapy schedule induces a HCV-RNA decrease and a Th1 network boost in HIV/HCV-coinfected patients.
    Perrella A; Sbreglia C; D'Antonio A; Atripaldi L; Perrella O
    Clin Microbiol Infect; 2010 Jun; 16(6):676-8. PubMed ID: 19681945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of hepatitis C virus (HCV) in serum and peripheral-blood mononuclear cells from HCV-monoinfected and HIV/HCV-coinfected persons.
    Blackard JT; Smeaton L; Hiasa Y; Horiike N; Onji M; Jamieson DJ; Rodriguez I; Mayer KH; Chung RT
    J Infect Dis; 2005 Jul; 192(2):258-65. PubMed ID: 15962220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Profile of patients triply infected with HIV and the hepatitis B and C viruses in the HAART era.
    Maida I; Ríos MJ; Pérez-Saleme L; Ramos B; Soriano V; Pegram PS; Mura MS; Sánchez-Margalet V; Saldívar-Cornejo I; Wilkin A; Babudieri S; Núñez M
    AIDS Res Hum Retroviruses; 2008 May; 24(5):679-83. PubMed ID: 18462085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of immunological and virological responses to antiretroviral therapy amongst HIV-infected adults in central Argentina: negative influence of hepatitis C infection.
    Farías AA; Kremer LE; Allende L; Díaz Mdel P; Pisano MB; Contigiani MS; Ré VE
    Trans R Soc Trop Med Hyg; 2013 Jul; 107(7):432-7. PubMed ID: 23761392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-infected inpatients in the HAART era: how do hepatitis C virus coinfected patients differ?
    Falusi OM; Pulvirenti J; Sarazine J; Shastri P; Gail C; Glowacki R
    AIDS Patient Care STDS; 2003 Jan; 17(1):13-6. PubMed ID: 12614516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.
    Pawlotsky JM; Pellerin M; Bouvier M; Roudot-Thoraval F; Germanidis G; Bastie A; Darthuy F; Rémiré J; Soussy CJ; Dhumeaux D
    J Med Virol; 1998 Apr; 54(4):256-64. PubMed ID: 9557291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals.
    Hopkins S; Lambourne J; Farrell G; McCullagh L; Hennessy M; Clarke S; Mulcahy F; Bergin C
    HIV Med; 2006 May; 7(4):248-54. PubMed ID: 16630037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study.
    Larsen MV; Omland LH; Gerstoft J; Røge BT; Larsen CS; Pedersen G; Obel N; Kronborg G
    Scand J Infect Dis; 2010 Dec; 42(11-12):917-23. PubMed ID: 20840000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significant differences in clinical outcomes between HIV-hepatitis C virus coinfected individuals with and without injection drug use history.
    Cescon A; Chan K; Raboud JM; Burchell AN; Forrest JI; Klein MB; Loutfy MR; Machouf N; Montaner JS; Tsoukas C; Hogg RS; Cooper C;
    AIDS; 2014 Jan; 28(1):121-7. PubMed ID: 24413263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy.
    Klein MB; Lalonde RG; Suissa S
    J Acquir Immune Defic Syndr; 2003 Jul; 33(3):365-72. PubMed ID: 12843748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Chronic hepatitis C in patients with HIV/HCV coinfection with high CD4+ lymphocytes count].
    Inglot M; Szymczak A; Gładysz A; Małyszczak K; Zalewska M
    Przegl Epidemiol; 2007; 61(3):535-43. PubMed ID: 18069391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy.
    Zaegel-Faucher O; Bregigeon S; Cano CE; Obry-Roguet V; Nicolino-Brunet C; Tamalet C; Dignat-George F; Poizot-Martin I
    AIDS; 2015 Jul; 29(12):1505-10. PubMed ID: 26244390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.